NeoStem Announces Approval for Listing on American Stock Exchange Under Ticker Symbols NBS and NBS.U Starting Thursday August 9,
August 09 2007 - 12:01AM
Business Wire
NeoStem, Inc. (OTCBB:NEOI), the first company to specialize in the
collection, processing and long term storage of stem cells from
healthy adults for personal use in times of critical medical need,
today announces its common stock and units have been approved to be
listed on the American Stock Exchange under the ticker symbols�NBS
and NBS.U�and will start trading August 9, 2007. The listing
followed the completion of a public-offering in excess of $5
million and a one-for-ten reverse stock split. The listing on the
American Stock Exchange is consistent with the Company�s strategic
mission to attract institutional investors and to provide long-term
value for its shareholders. �We are extremely proud of our recent
achievements and of surpassing yet another milestone for the
benefit of our shareholders,� said Robin Smith, M.D., Chairman and
Chief Executive Officer of NeoStem. �It is an honor to be listed on
the American Stock Exchange and to enjoy all the benefits of its
long and storied history. We believe these recent developments will
be major catalysts as we move forward into a position of leadership
in the burgeoning market for stem cell therapies and services.� The
closing of this offering is the latest validation of NeoStem�s
high-growth business model focused on developing next generation
services and therapies that have the potential to help millions of
health-conscious individuals. The total offering comprises units at
a price of $5 per unit. Each unit consists of one share of common
stock and one-half a Class A warrant to purchase one-half a share
of common stock. Thus, 1,000 units consist of 1,000 shares and
warrants to purchase 500 shares of common stock. The Underwriter
for the offering was Mercer Capital Ltd., members of the National
Association of Securities Dealers, Inc. NeoStem�s common stock,
units and Class A warrants have been accepted for listing on the
American Stock Exchange under the symbols �NBS�, �NBS.U�, and
�NBS.WS� respectively, effective upon consummation of the initial
closing of the offering. The CUSIP for the Common Stock is
640650305, the CUSIP for the Units is 640650206, and the CUSIP for
the Warrants is 640650115. NeoStem�s first-to-market competitive
advantage uniquely positions the Company to capitalize on the
hundreds of adult stem cell-based therapy clinical trials currently
underway. As these stem cell-based therapies become available,
NeoStem clients will be among the first to benefit from the life
saving progress that has already been made for such debilitating
conditions as cancer, heart disease, multiple sclerosis, lupus, and
many others. About NeoStem, Inc. NeoStem is a biotechnology
services company enhancing the delivery of adult stem cell
therapeutics to health-conscious consumers. The Company is
developing a nationwide network of adult stem cell collection
centers, enabling people to donate and store their own stem cells
with NeoStem for personal use years or decades later in times of
critical medical need. The proprietary NeoStem technologies empower
health-conscious consumers to help protect their future health by
undergoing treatment with their own stem-cells - providing an
accessible supply of healthy, genetically matched stem cells for
use in the eventuality of illness. Currently underway are hundreds
of stem cell-based research programs and clinical trials
investigating the use of these non-controversial adult stem cells,
such as those collected from donors under NeoStem's methods. As the
nation's population ages and encounters serious age-related and
congenital health issues, NeoStem has positioned itself as a leader
in the fast-growing national trend toward personal "bio-insurance."
The Company's non-capital intensive business plan is a service
model that is completely scalable, thus minimizing risk levels
ordinarily related to most long-term biopharmaceutical research and
development. Under its strategic business plan, NeoStem has begun
opening a nationwide network of adult stem cell collection
facilities. Its stem cell collection systems will be located in
existing physician offices and medical facilities, where the
procedures and care can be administered by trusted personal doctors
and medical professionals. For more information, please visit:
www.neostem.com. For other information and resources about the
Company, visit www.CFSG1.com or
www.trilogy-capital.com/tcp/neostem/quote.html. Forward-Looking
Statements Certain statements in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
concerning the ability of NeoStem, Inc. ("the Company") to develop
the adult stem cell business, the future of regenerative medicine
and the role of adult stem cells in that future, the future use of
adult stem cells as a treatment option and the potential revenue
growth of the Company's business. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, performance or achievements of
the Company, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. The Company's ability
to enter the adult stem cell arena and future operating results are
dependent upon many factors, including but not limited to (i) the
Company's ability to obtain sufficient capital or a strategic
business arrangement to fund its expansion plans; (ii) the
Company's ability to build the management and human resources and
infrastructure necessary to support the growth of its business;
(iii) competitive factors and developments beyond the Company's
control; (iv) scientific and medical developments beyond the
Company's control; (v) the Company's inability to obtain
appropriate state licenses or any other adverse effect or
limitations caused by government regulation of the business; and
(vi) other risk factors discussed in the Company's periodic filings
with the Securities and Exchange Commission which are available for
review at www.sec.gov under "Search for Company Filings." Pursuant
to an October 1, 2006 agreement, Consulting For Strategic Growth I,
Ltd. ("CFSG1") provides the Company with consulting, business
advisory, investor relations, public relations and corporate
development services, for which CFSG1 receives a fixed monthly fee
for the duration of the agreement and received shares of NeoStem's
common stock. Independent of CFSG1's receipt of cash or other
compensation from the Company, CFSG1 may choose to purchase the
common stock of the Company and thereafter sell those shares at any
time it deems appropriate to do so. For more information, please
visit www.cfsg1.com.
Neostem (AMEX:NBS.U)
Historical Stock Chart
From Apr 2024 to May 2024
Neostem (AMEX:NBS.U)
Historical Stock Chart
From May 2023 to May 2024